PEPTIDESTAT
InvestigationalWeight lossSubcutaneousEvidence 4/5

Cagrilintide

Also known as: AM833

Long-acting amylin analog that slows gastric emptying and reinforces satiety; studied in combination with semaglutide (CagriSema).

Browse guidesBuy / compare source
Cagrilintide
Drug class
Amylin analog
Primary targets
Amylin / CTR
Dose reference
Trial doses up to 4.5 mg weekly
Half-life
~7 days
Developer / origin
Novo Nordisk
Reference year
2021
Evidence score
4/5 - Phase 2 human evidence
Evidence 4/5

Phase 2 human evidence

Cagrilintide has randomized phase 2 human weight-management data and combination evidence with semaglutide, but it remains investigational.

Investigational compound with human randomized or phase 2/3 evidence.

Evidence basis

  • Human phase 2 obesity trial
  • CagriSema clinical development
  • No approved indication yet

How to read this entry

Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.

Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.

Cagrilintide guides

Read the matching guide or adjacent research pages for more context.

Pramlintide: Amylin Analog Evidence, Weight Loss and Safety LimitsPramlintide is the approved amylin analog behind Symlin, but its weight-loss story is narrower than newer obesity-amylin marketing suggests.Cagrilintide: Amylin Evidence, CagriSema Results and SafetyCagrilintide is an investigational amylin analog. The strongest interest is CagriSema, Novo Nordisk's cagrilintide plus semaglutide combination.Peptides for Weight Loss: GLP-1s, Tirzepatide, Retatrutide and What WorksA broad guide to weight-loss peptides, from approved GLP-1 and dual-incretin medicines to investigational retatrutide, cagrilintide and other research compounds.GLP-1 for Weight Loss: How Well They Work, and What They CostGLP-1 weight-loss drugs produce 8–21% average body-weight reduction in trials. The honest version weighs eligibility, results, cost, side effects, and the rebound after you stop.

Cagrilintide calculator shortcuts

Open peptide calculators with editable Cagrilintide example values already filled in.

Cagrilintide accumulation calculatorPrefills 168 hour half-life and 168 hour interval examples.Open prefilled tool

Peptide calculators

Use calculators for concentration, unit conversion and repeated-dose accumulation math.

Peptide reconstitution calculatorCalculate concentration, draw volume and syringe units from vial strength and BAC water.Open toolPeptide accumulation calculatorModel repeated dosing schedules with half-life, interval, peak and trough estimates.Open toolPeptide unit converterConvert mg, mcg, optional IU and syringe units from one reconstituted vial setup.Open toolPeptide chemistry calculatorAnalyze sequence length, molecular weight, composition, charge, hydropathy and notation.Open tool

Compare with related peptides

Stay inside the same research category and compare mechanism, status and evidence quality.

Retatrutide

LY3437943

4/5
Weight lossInvestigational

Activates GLP-1, GIP and glucagon receptors simultaneously to suppress appetite and raise energy expenditure.

DetailsGuide

Tirzepatide

LY3298176, Mounjaro, Zepbound

5/5
Weight lossApproved

Activates GLP-1 and GIP receptors to improve glycemic control and reduce appetite + body weight.

DetailsGuide

Semaglutide

Ozempic, Wegovy, Rybelsus

5/5
Weight lossApproved

Mimics the incretin GLP-1, slowing gastric emptying and reducing appetite while improving insulin secretion.

DetailsGuide

Liraglutide

Victoza, Saxenda

5/5
Weight lossApproved

Daily GLP-1 analog. Reduces appetite and improves glycemic control via the same incretin pathway as semaglutide.

DetailsGuide

Category hub

Open the category page for the full comparison table and FAQ.

Weight Loss Peptides

Compare weight loss peptides including GLP-1, GIP, amylin and triple-agonist compounds by approval status, mechanism, half-life and evidence score.

Research & educational purposes only

The information on PeptideStat is for educational and research purposes only and is not medical advice. Many peptides discussed are research compounds not approved for human use. Always consult a qualified healthcare professional before making any health decisions. Articles may contain affiliate links — we may earn a commission at no extra cost to you.